多发质瘤和单发质瘤的不同危险因素:放射学,病理学和临床特征的比较研究
Limei Feng1, Xinyao Shi1, Yuying Zang2
1Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Frontiers in oncology
|June 11, 2025
概括
多重质瘤与年龄较大,男性性别相关,与单焦质瘤相比,结果更差. 深度瘤位置是多重质瘤的关键风险因素,影响生存率.
科学领域:
- 神经瘤学神经瘤学
- 神经外科 神经外科
- 病理学 病理学 病理学
背景情况:
- 单焦质瘤和多重质瘤的回顾性比较.
- 人口,临床,成像和病理特征的分析.
- 预后因素和临床结果的评估.
研究的目的:
- 为了比较单焦与多重质瘤的特征和结果.
- 区分多焦点和多中心质瘤亚型.
- 为了确定质瘤亚型的风险因素和预后指标.
主要方法:
- 对188种单点性质瘤和94种多点性质瘤进行了回顾性分析.
- 临床,MRI,病理学数据和生存率的比较.
- 人口,放射和病理特征的统计分析.
主要成果:
- 多重质瘤显示年龄较大,男性占主导地位,切除范围较小,预后更差.
- 多重质瘤与非表面位置,,强烈增强,更高的WHO等级,更低的IDH突变和1p19q代选择有关.
- 瘤的位置和IDH状态是多重质瘤的独立风险因素;深部位置预测了不良的OS.
- 多焦质瘤在男性中更常见;多焦质瘤和多中心质瘤之间的位置不同.
- 世卫组织的等级是多中心质瘤的预后,但不是多焦点质瘤.
结论:
- 人口统计学,放射学,病理学和预后因素在单焦质瘤和多重质瘤之间有所不同.
- 多焦点质瘤和多中心质瘤之间的临床和放射性特征各不相同.
- 表面多中心质瘤的预后与世卫组织等级相关,指导临床管理.
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...


